Related Experiment Video

Updated: Sep 5, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.1K

Thrombotic Microangiopathy Syndromes-Common Ground and Distinct Frontiers

Ramy M Hanna1, Kammi Henriksen2, Kamyar Kalantar-Zadeh1

  • 1UCI Medical Center Department of Medicine, Division of Nephrology, University of California Irvine, Orange, CA.

Advances in Chronic Kidney Disease
|July 11, 2022
PubMed

Insights

Thrombotic microangiopathies (TMAs) are diverse conditions sharing anemia and organ damage. Understanding their distinct causes, like complement dysregulation in atypical hemolytic uremic syndrome, is crucial for targeted therapies.

Area of Science:

  • Nephrology
  • Hematology
  • Rheumatology

Background:

  • Thrombotic microangiopathies (TMAs) present with microangiopathic hemolytic anemia and end-organ dysfunction.
  • Distinct TMAs include thrombotic thrombocytopenic purpura (TTP), Shiga toxin-mediated hemolytic uremic syndrome (ST-HUS), and atypical hemolytic uremic syndrome (aHUS).
  • Secondary TMAs arise from drug-induced, rheumatological, or renal-limited conditions, often involving complement activation.

Purpose of the Study:

  • To delineate the spectrum of Thrombotic Microangiopathies (TMAs).
  • To highlight the underlying mechanisms and clinical distinctions between various TMA subtypes.
  • To underscore the emerging importance of TMAs in nephrology, rheumatology, and hematology.

Main Methods:

  • Review of existing literature on TMA pathogenesis and clinical presentations.
  • Classification of TMAs based on underlying etiology and pathophysiology.
  • Comparative analysis of clinical features and therapeutic responses across TMA subclasses.

Main Results:

  • TMAs share a common phenotype but differ in etiology: TTP (von Willebrand factor), ST-HUS (Shiga toxin), and aHUS (complement dysregulation).
  • Secondary TMAs and renal-limited TMAs involve complement activation, with some cases resembling aHUS.
  • Hematopoietic stem cell transplant-TMA presents unique challenges and therapeutic requirements.

Conclusions:

  • TMAs represent a complex and evolving group of disorders requiring multidisciplinary approaches.
  • Further research into genetics, molecular biology, and therapeutics is essential for distinguishing and treating TMA subtypes.
  • Understanding TMA heterogeneity is critical for advancing patient care in nephrology, rheumatology, and hematology.
Keywords:
Atypical hemolytic uremic syndromeAutoantibody complement inhibitorsComplementThrombotic microangiopathyThrombotic thrombocytopenic purpura

More Related Videos

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.1K
Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.0K

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
31
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
39
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
879
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
21
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
29